Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-3463275 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-3463275 | DRUG | PF-3463275 10mg |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Diagnosis of schizophrenia * In stable treatment with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone for at least 2 months * Stable symptoms of schizophrenia for at least 3 months. Exclusion Criteria: * Subjects with a psychiatric disorder ot...
PF-3463275 is an investigational small molecule being studied as an adjunctive treatment for cognitive deficits in schizophrenia. It was evaluated in a Phase 1 clinical trial in the United States. The drug is not approved and remains in clinical development.
PF-3463275 is a small molecule, but its specific molecular target has not been disclosed. The drug is being investigated for its potential to address cognitive deficits associated with schizophrenia, though the exact mechanism of action is not publicly detailed.
PF-3463275 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company sponsored the clinical trial for this investigational drug.
PF-3463275 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not been approved by regulatory authorities.
PF-3463275 has been studied in one completed clinical trial, identified as NCT00567203. This Phase 1 study, titled 'A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia,' enrolled 36 participants in the United States and evaluated the drug as an adjunctive treatment.
PF-3463275 is the primary identifier for this investigational drug. No alternative names have been associated with it in the available clinical trial information. It is a distinct small molecule being developed by Pfizer.